Understanding how STING affects T cell death and cancer immunity
Official title: Deciphering the Roles of STING-Mediated T cell Pyroptosis in Antitumor Immunity
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10854276 · Data updated 2026-11-12
This study is looking at how a protein called STING affects the immune system's ability to fight cancer, especially how it can help or hinder T cells, which are important for battling tumors, to find out why some cancer treatments don't work as well as they should and to discover new ways to improve those treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $467,502 |
| NIH project number | 1R37CA288747-01 |
| Project ID | NIH-10854276 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are resistant to existing immunotherapies, particularly those involving T cell therapies.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors are not influenced by STING-mediated pathways may not benefit from this research.
What this research studies
This research investigates the role of the STING protein in the immune response against tumors, particularly focusing on how it can both activate and inhibit T cells, which are crucial for fighting cancer. By studying the mechanisms of STING-mediated cell death in T cells within the tumor microenvironment, the research aims to uncover why some cancer treatments fail. The approach involves analyzing how STING activation influences various immune cells and their interactions in the presence of tumors. This could lead to new strategies to enhance the effectiveness of cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by overcoming resistance to current therapies.
How similar studies have gone: Previous research has shown that targeting immune pathways like STING can enhance antitumor responses, indicating potential for success in this area.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Wu, Jianjun — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Wu, Jianjun
Related research
Other NIH-funded projects on the same topics.
-
Susceptibility-based MRI biomarkers for multiple sclerosis
A short-term study aims to test MRI biomarkers that could help diagnose and predict MS in patients, using advanced imaging techniques.
-
Population genomics in peripartum cardiomyopathy
A gene-focused study to understand why some women develop heart failure around and after pregnancy, with an emphasis on African ancestry.
-
Broad antiviral therapy by targeting a key enzyme in nucleotide synthesis
A plan to block a human enzyme that many viruses need, with the aim of creating a broad-spectrum antiviral treatment for infections like SARS-CoV-2, influenza, and HSV-1.
-
Cellular-level Vascular Oculomics for Monitoring Systemic Vascular Health
A multi-site project using eye imaging and AI to monitor blood vessel health in people, with devices and software developed across four clinical sites.
-
Cellular-level Eye Signals to Track Vascular Health
A multi-site project aims to create and test portable imaging devices and AI tools that can monitor blood vessel health through the eye.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.